These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29519869)

  • 1. Dexamethasone in hyperleukocytic acute myeloid leukemia.
    Bertoli S; Picard M; Bérard E; Griessinger E; Larrue C; Mouchel PL; Vergez F; Tavitian S; Yon E; Ruiz J; Delabesse E; Luquet I; Linares LK; Saland E; Carroll M; Danet-Desnoyers G; Sarry A; Huguet F; Sarry JE; Récher C
    Haematologica; 2018 Jun; 103(6):988-998. PubMed ID: 29519869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.
    Bertoli S; Paubelle E; Bérard E; Saland E; Thomas X; Tavitian S; Larcher MV; Vergez F; Delabesse E; Sarry A; Huguet F; Larrue C; Bosc C; Farge T; Sarry JE; Michallet M; Récher C
    Eur J Haematol; 2019 Feb; 102(2):131-142. PubMed ID: 30325535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
    Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
    Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.
    Canaani J; Labopin M; Socié G; Nihtinen A; Huynh A; Cornelissen J; Deconinck E; Gedde-Dahl T; Forcade E; Chevallier P; Bourhis JH; Blaise D; Mohty M; Nagler A
    Am J Hematol; 2017 Jul; 92(7):653-659. PubMed ID: 28370339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of NPM1 mutated acute myeloid leukemia: A single-institution experience.
    Sayar H; Bashardoust P; Cripe L; Chakraborty S; Bai S
    Am J Hematol; 2017 Feb; 92(2):E17-E18. PubMed ID: 27813149
    [No Abstract]   [Full Text] [Related]  

  • 8. Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis.
    Cerrano M; Chevret S; Raffoux E; Rabian F; Sébert M; Valade S; Itzykson R; Lemiale V; Adès L; Boissel N; Dombret H; Azoulay E; Lengliné E
    Ann Hematol; 2023 Apr; 102(4):761-768. PubMed ID: 36773040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
    Zidan MA; Kamal Shaaban HM; Elghannam DM
    Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia.
    Fu Y; Zhu H; Wu W; Xu J; Chen T; Xu B; Qian S; Li J; Liu P
    Leuk Lymphoma; 2014 Feb; 55(2):371-7. PubMed ID: 23713453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
    Tiribelli M; Raspadori D; Geromin A; Cavallin M; Sirianni S; Simeone E; Bocchia M; Fanin R; Damiani D
    Leuk Res; 2017 Jul; 58():31-38. PubMed ID: 28407515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
    Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
    Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma.
    Dubinski D; Won SY; Gessler F; Quick-Weller J; Behmanesh B; Bernatz S; Forster MT; Franz K; Plate KH; Seifert V; Harter PN; Senft C
    J Neurooncol; 2018 May; 137(3):503-510. PubMed ID: 29349612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
    Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.
    Boyer T; Guihard S; Roumier C; Peyrouze P; Gonzales F; Berthon C; Quesnel B; Preudhomme C; Behal H; Duhamel A; Roche-Lestienne C; Cheok M
    Oncotarget; 2016 Sep; 7(38):62377-62385. PubMed ID: 27566555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.